Visalytics
Visalytics
approved EB-2 (NIW)

Researcher

Pharmaceutical Science · South Korea · 2025-03-24

Processing Time
54 days
Decision Date
2025-03-24
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue her research in pharmaceutical science by integrating advanced technologies and computational approaches to develop novel drug candidates. Her work focuses on improving drug delivery systems to create more effective, affordable, and stable medications for chronic diseases including cancer, diabetes, hypertension, and neurodegenerative diseases.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses urgent public health challenges and enhances the management of chronic diseases in the U.S.

2 Well-positioned to Advance the Endeavor Met

The petitioner's record of 12 publications, 281 citations, and previous research funding demonstrates her ability to succeed.

3 Waiver Benefit Met

On balance, the petitioner's contributions to pharmaceutical stability and affordability justify waiving the labor certification.

Why This Petition Was Approved

The petition was approved based on the petitioner's Master's degree in pharmacy and her record of 12 peer-reviewed journal articles and 10 conference abstracts. Her work earned 281 citations and received funding from major institutions like the National Research Foundation of Korea. The case satisfied all three Dhanasar prongs, demonstrating national importance and that she is well-positioned to advance her research.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Dependent
Grants
Conference Presentations

Similar Cases

Research Scientist

Pharmaceuticals · China

WeGreened EB-2 (NIW) approved
Illinois 110 days 2023-02-02
The petitioner proposes to conduct research combining pharmacoepidemiology, pharmacoeconomics, and health outcomes science to identify treatment risks and prescribing patterns. Her work focuses on uncovering disease mechanisms and patient outcomes in chronic conditions like COPD, liver disease, and breast cancer to inform better diagnostic and therapeutic strategies. The endeavor aims to improve healthcare delivery efficiency and public health innovation within the United States.
View Case

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) rfe approved
North Carolina 111 days 2025-02-08
The petitioner proposes to improve existing therapies by applying advanced pharmaceutical principles to commercialize biopharmaceuticals and pharmaceuticals. The work focuses on developing innovative drug solubility enhancement methods and non-invasive oral drug delivery systems to treat serious diseases like cancer, AIDS, and kidney failure.
View Case

Postdoctoral Researcher

Chemicals · India

WeGreened EB-2 (NIW) approved
Massachusetts 156 days 2022-10-04
The petitioner proposes to continue research on developing state-of-the-art drug delivery approaches that cross biological interfaces. This work focuses on enabling the facile treatment of a wide range of disorders, including neurological disorders, metastatic cancer, and COVID-19, through protein-based therapies.
View Case

Research Assistant

Pharmaceuticals · China

WeGreened EB-2 (NIW) approved
California 426 days 2025-01-08
The petitioner proposes to continue research in pharmaceutical chemistry with a focus on drug discovery optimization and the development of advanced computational techniques. This work involves identifying new therapeutics for human diseases and creating computational methods that offer significant advantages over conventional drug discovery approaches. The intended impact is to reduce the economic and social costs of disease while improving global public health.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from South Korea

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-03-24.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 54 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in South Korea All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist